INTRODUCTION
D-Amino acid oxidase (DAAO, EC 1.4.3.3) catalyzes the oxidative deamination of D-amino acids to produce their corresponding α-keto acids. 1, 2) D-Serine, which is an endogenous coagonist at the glycine-binding site of N-methyl-D-aspartate (NMDA) receptors, is metabolized by DAAO. 3, 4) The gene encoding DAAO is one of the susceptibility genes for schizophrenia 4) and is asso- * To whom correspondence should be addressed: Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Toho University, 2-2-1 Miyama, Funabashi 274-8510, Japan. Tel. & Fax: +81-47-472-1504; E-mail: tfukushima@phar.toho-u.ac.jp ciated with hypofunction of the NMDA receptors in the brain. Schizophrenia is a severe psychiatric disease with symptoms that include auditory hallucinations, paranoid or bizarre delusions, and disorganized speech and thinking with significant social or occupational dysfunction. 5) We previously reported that serum D-serine concentrations were significantly decreased in schizophrenic patients. 6) In addition, co-administration of D-serine with antipsychotic drugs is effective for the treatment of schizophrenia. 7) Further, because brain Dserine is metabolized by DAAO, suppression of Dserine metabolism may improve the symptoms of schizophrenia. Thus, a screening assay for a DAAO inhibitor is crucial for the discovery of novel drugs for the treatment of schizophrenia.
Kynurenic acid (KYNA) antagonizes both NMDA receptor function by interacting with the glycine-binding site and α 7 nicotinic acetylcholine receptor activity. 8, 9) In the course of our studies, we found that D-kynurenine (D-KYN), a D-amino acid, may be metabolized to KYNA by DAAO in vivo. 10, 11) We reported that an increase of plasma KYNA concentration was observed in rats after the administration of D-KYN. 10) In addition, a remarkable amount of KYNA was produced in the extracellular fluid of rat prefrontal cortex during D-KYN infusion. 11) Considering these findings, oxidative deamination of the α-amino group of D-KYN by DAAO may result in the production of KYNA through an intermediate α-keto acid (Fig. 1) .
In the present study, the enzymatic formation of KYNA from D-KYN was investigated in vitro by using pig kidney DAAO (pkDAAO). Additionally, we developed a fluorescence assay based on the intrinsic fluorescence property of KYNA, to test whether DAAO could convert D-KYN into KYNA for the screening of DAAO inhibitors.
There have been reports of DAAO inhibitors such as benzoic acid, 12) 5-methylpyrazole-3-carboxylic acid (MPC; AS057278), 13) 14, 15) 3-hydroxyquinoline-2(1 H)-one, 16) and 5-carboxyfuro[3,2-b]pyrrole. 17) Of these inhibitors, MPC was chosen as an authentic compound for our studies, and the IC 50 value of MPC for pkDAAO was determined. We also examined the inhibition of DAAO by Dalanine, D-serine, and chlorpromazine when D-KYN was used as a substrate. According to the following equation, the ΔF value was determined and used to calculate the kinetic parameters, K m and V max , by using a Lineweaver-Burk plot. To confirm the results by MS, D-KYN (100 µM) was reacted with DAAO as described, and the resulting sample was diluted with methanol without adding zinc acetate. Subsequently, the diluted sample was infused at a rate of 10 µl/min into the mass spectrometer. All MS data were acquired on an LCQ ion trap MS (ThermoFisher Scientific, Yokohama, Japan) equipped with an electrospray ionization source in the positive-ion mode. The experimental conditions were as follows: spray needle voltage, 5 kV; heated capillary temperature, 200 • C; and sheath gas flow rate, 40 (arbitrary units). MS were obtained using full ion-scan mode over a massto-charge (m/z) range of 100-2000. High-performance Liquid Chromatography (HPLC) --After the enzymatic reaction of D-KYN (100 µM) with DAAO as described, the resulting solution was diluted 200-fold with H 2 O/CH 3 CN (95/5) containing 50 mM ammonium acetate (mobile phase), and a 5.0-µl aliquot of the final solution was injected onto column-switching HPLC with fluorescence detection (ex. 251 nm, em. 398 nm) as reported. 10, 11) Five µl of the KYNA standard (5.0 nM in the mobile phase) was also injected for the comparison of retention times. DAAO Assay with Test Compounds --For the inhibition assay of DAAO, 50 µl of the test compounds (concentrations, 2.5-10000 µM) was added to 1000 µM D-KYN, and DAAO activity was assayed as described. For the inhibition curve, the final concentrations of the test compounds were plotted on the x-axis, and the ΔF value in the absence of the inhibitor was set as 100% on the y-axis. The degree of inhibition of each test compound was expressed as a percentage according to the following equation:
Remaining activity of pkDAAO (%) = ΔF /ΔF × 100 (2) ΔF is the ΔF value at each concentration of the inhibitor.
RESULTS AND DISCUSSION
In Vitro Production of KYNA Our recent findings on KYNA production from D-KYN in vivo 10, 11) suggested that D-KYN is metabolized to KYNA by DAAO. In the present study, we examined whether KYNA formation from D-KYN could occur in vitro by using a commercial pkDAAO. As shown in Fig. 2 (a) , the excitation and emission spectra of the product generated by the enzymatic reaction of DAAO with D-KYN were consistent with those reported for KYNA, and the fluorescence intensity was dependent on the D-KYN concentration. The mass spectrum of the enzymatic product clearly showed a pseudomolecular ion ([M + H] + ) peak at m/z 190.0, which is consistent with KYNA, in the positive-ionization mode [ Fig. 2 (b) ]. In addition, a peak with a retention time that was identical to that of KYNA was observed [ Fig. 2 (c) ] when the enzymatic product was injected onto a column-switching HPLC system we used previously. 10, 11) These results suggest that DAAO was responsible for the production of KYNA from D-KYN in this in vitro assay. To date, the K m and V max of D-KYN for DAAO have not been published; however, based on the Lineweaver-Burk plot of our data (Fig. 3) , K m and V max were 148 µM and 5.53 µmol/min per mg, respectively. These values indicate that D-KYN has a high affinity for DAAO. From the increased fluorescence, ΔF in Eq. (1), the amount of KYNA produced from D-KYN can be determined from the standard curve of KYNA (r 2 = 0.9958). The ΔF value can be used to evaluate DAAO activity as described below. When zinc acetate is added to the boric acid buffer solution, a slight sediment is produced. However, this sediment can be removed by centrifugation without affecting fluorescence measurements. The assay precision (i.e., the relative standard deviation) was within 3.25% (n = 3).
In previous research involving DAAO assays, mainly α-keto acid or hydrogen peroxide (H 2 O 2 ), both of which are produced in the enzymatic reaction of D-amino acids with DAAO, have been used in the subsequent colorimetric assay. Since α-keto acid can react with 2,4-dinitrophenylhydrazine to produce its hydrazone, the visible absorption of hydrazone can be assessed to monitor DAAO activity. 22) On the other hand, the produced H 2 O 2 is used for the oxidation of a colorimetric reagent such as o-dianisidine by peroxidase, 12) and the visible absorption of the oxidized reagent can be assessed to monitor DAAO activity. Compared to these previous methods, the proposed assay is simple and facile because it uses the fluorescence intensity of KYNA produced from D-KYN through one enzymatic reaction step by DAAO.
Inhibition by MPC, a DAAO Inhibitor
KYNA itself emits fluorescence, especially in the presence of zinc ions; [23] [24] [25] [26] therefore, the procedure described above can be used to evaluate in vitro DAAO activity. A test compound was added to the enzymatic reaction of DAAO with D-KYN. If the compound inhibits DAAO activity, a significant attenuation in the ΔF value [i.e., a small ΔF value, Eq. (2)] will be observed. Figure 4 shows dosedependent inhibition curves of pkDAAO by test compounds. The remaining activity of pkDAAO (%) can be used as a measure of the inhibitory activity of the test compound at each concentration. We first tested MPC, which was originally developed as a specific inhibitor of DAAO. 13) As shown in Fig. 4 (a) , a remarkable attenuation of fluorescence, which reflects an inhibition of pkDAAO activity, was clearly observed in the presence of MPC at concentrations above 0.5 µM. In the present study, the IC 50 of MPC was approximately 3.4 µM, which is slightly higher than the reported value (0.91 µM). 13) This slight difference may be due to differences in the origin of the DAAO enzymes or in the assay procedures between the studies.
Inhibition by D-serine or D-alanine
As shown in Fig. 4 (b) and 4 (c), D-serine and Dalanine, which are endogenous D-amino acids, inhibited DAAO activity in our assay (n = 4). The IC 50 values of D-serine and D-alanine were approximately 0.85 mM and 0.89 mM, respectively. These D-amino acids are known to be easily metabolized by DAAO, and the K m of D-serine and D-alanine for pkDAAO is reported to be 41 mM and 3.1 mM, respectively. 18) Therefore, competitive inhibition at the reactive site of DAAO may occur between D-KYN and these D-amino acids.
Inhibition by Chlorpromazine
We tested chlorpromazine, a tricyclic antipsychotic drug, because it has been reported to inhibit DAAO activity in vitro. 27, 28) In the present study, chlorpromazine at concentrations above 10 mM clearly inhibited DAAO activity, and the IC 50 was approximately 1.9 mM [n = 3, Fig. 4 (d) ]. The inhibitory mechanism of chlorpromazine is believed to be different from that of D-alanine and D-serine. One report suggested that chlorpromazine displaces FAD, a cofactor necessary for DAAO activity. 27) In this study, we verified that our assay can be used to monitor DAAO activity by testing several compounds that inhibit DAAO. We have established a facile assay for measuring DAAO activity using D-KYN as a substrate. This method will be used to screen for additional inhibitors of DAAO.
